MedTrace Logo

Prevention of Cardiovascular Complications in Diabetic Patients With Vitamin E Treatment

NCT00220831 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2007-03-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether Vitamin E treatment to Diabetic patients, who carry the Haptoglobin 2-2 Phenotype, prevents cardiovascular complications such as acute MI and Stroke.

Conditions

Interventions

DRUG

Natural source Vitamin E 400IU/day

Sponsors & Collaborators

  • Clalit Health Services

    collaborator OTHER

  • The Kennedy Leigh Charitable Trust

    collaborator OTHER

  • Technion, Israel Institute of Technology

    lead OTHER

Principal Investigators

  • Uzi Milman, MD · Clalit Health Services

  • Chen Shapira, MD · Clalit Health Services

  • Shany Blum, MD MSc · Laboratory of Vascular Medicine, the Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology.

  • Andrew P Levy, MD PhD · Laboratory of Vascular Medicine, the Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2009-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00220831 on ClinicalTrials.gov